- Home
- RAPT vs ELUT Comparison
RAPT vs ELUT Comparison
Compare RAPT & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAPT
- ELUT
- Stock Information
- Founded
- RAPT 2015
- ELUT 2015
- Country
- RAPT United States
- ELUT United States
- Employees
- RAPT N/A
- ELUT N/A
- Industry
- RAPT Biotechnology: Pharmaceutical Preparations
- ELUT Medical Specialities
- Sector
- RAPT Health Care
- ELUT Health Care
- Exchange
- RAPT Nasdaq
- ELUT Nasdaq
- Market Cap
- RAPT 117.5M
- ELUT 94.0M
- IPO Year
- RAPT 2019
- ELUT 2020
- Fundamental
- Price
- RAPT $0.89
- ELUT $1.80
- Analyst Decision
- RAPT Buy
- ELUT Strong Buy
- Analyst Count
- RAPT 5
- ELUT 2
- Target Price
- RAPT $5.25
- ELUT $8.00
- AVG Volume (30 Days)
- RAPT 1.1M
- ELUT 43.3K
- Earning Date
- RAPT 05-08-2025
- ELUT 05-08-2025
- Dividend Yield
- RAPT N/A
- ELUT N/A
- EPS Growth
- RAPT N/A
- ELUT N/A
- EPS
- RAPT N/A
- ELUT N/A
- Revenue
- RAPT N/A
- ELUT $23,711,000.00
- Revenue This Year
- RAPT N/A
- ELUT $37.67
- Revenue Next Year
- RAPT N/A
- ELUT $63.22
- P/E Ratio
- RAPT N/A
- ELUT N/A
- Revenue Growth
- RAPT N/A
- ELUT N/A
- 52 Week Low
- RAPT $0.71
- ELUT $1.61
- 52 Week High
- RAPT $4.60
- ELUT $5.24
- Technical
- Relative Strength Index (RSI)
- RAPT 48.13
- ELUT 43.69
- Support Level
- RAPT $0.81
- ELUT $1.61
- Resistance Level
- RAPT $1.27
- ELUT $1.89
- Average True Range (ATR)
- RAPT 0.14
- ELUT 0.15
- MACD
- RAPT 0.01
- ELUT 0.02
- Stochastic Oscillator
- RAPT 31.55
- ELUT 41.30
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
About ELUT Elutia Inc.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.